Levosulpiride Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:443990153
Atc Prefix:N05
Atc Suffix:AL07
Cas Number:23672-07-3
Pubchem:688272
Iuphar Ligand:958
Drugbank:DB00391
Chemspiderid:599749
Unii:JTG7R315LK
Kegg:D07312
Chebi:64119
Chembl:267044
Dtxsid:DTXSID0042583
Iupac Name:N-(2S)-1-ethylpyrrolidin-2-ylmethyl]-2-methoxy-5-sulfamoylbenzamide
C:15
H:23
N:3
O:4
S:1
Smiles:CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
Stdinchi:1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
Stdinchikey:BGRJTUBHPOOWDU-NSHDSACASA-N

Levosulpiride, sold under the brand name SULPEPTA , is a potent prokinetic agent of the benzamide class.[1] It is a selective antagonist of the dopamine D2 receptors and 5-HT4 agonist[2] on both central and peripheral nervous systems. Levosulpiride is claimed to have mood elevating properties.

Chemically, it is the (S)-(−)-enantiomer of sulpiride.

Uses

Levosulpiride is used in the treatment of:

Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.

Side effects

Side effects include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.[3] In the U.S., as of 2013 only one case of adverse reaction to levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.[4] A case of rapid onset resistant dystonia caused by low dose levosulpiride was reported in India.[5]

Mechanism of action

In contrast to most other neuroleptics which block both D1 and D2 receptors, levosulpiride is more selective and acts primarily as a D2 antagonist. Levosulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, and gamma-aminobutyric acid (GABA) receptors.[6]

Pharmacodynamics

Levosulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.[6]

See also

Notes and References

  1. Web site: Levosulpiride - S-(-)-Sulpiride . Generon . 2016-08-31.
  2. Web site: Levosulpiride . Stratech Scientific Ltd . 2016-08-31.
  3. Web site: Levosulpiride drug information . DrugsUpdate India .
  4. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F . 6 . Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database . Drug Safety . 36 . 6 . 467–79 . June 2013 . 23553446 . 3664739 . 10.1007/s40264-013-0032-z .
  5. Naskar S, Nath K . Rapid onset resistant dystonia with low dose of Levosulpiride. . British Journal of Psychiatry . 190 . 1 . January 2007 . 81 . 10.1192/bjp.190.1.81a . free .
  6. Web site: Sulpiride . DB00391 . DrugBank .